SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death

References

• Wiss L M, Movahed L A, Warnke R A, Sklar J. Detection of Epstein–Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320: 502–506
   PubMed Web of Science ®Google Scholar
• Kwon J M, Park Y H, Kang J H, Kim K, Ko Y H, Ryoo B Y, et al. The effect of Epstein–Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006; 85: 463–468
   PubMed Web of Science ®Google Scholar
• Griffin B E. Epstein–Barr virus (EBV) and human disease: facts, opinions and problems. Mutat Res 2000; 462: 395–405
   PubMedGoogle Scholar
• Fahraeus R, Fu H L, Ernberg I, Finkle J, Rowe M, Klein G, et al. Expression of Epstein–Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42: 329–338
   PubMed Web of Science ®Google Scholar
• Bonnet M, Guinebretiere J M, Kremmer E, Grunewald V, Benhamou E, Contesso G, et al. Detection of Epstein–Barr virus in invasive breast cancers. J Natl Cancer Inst 1999; 91: 1376–1381
   PubMed Web of Science ®Google Scholar
• Peng M, Lundgren E. Transient expression of the Epstein–Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992; 7: 1775–1782
   PubMed Web of Science ®Google Scholar
• Brennan P, Floettmann J E, Mehl A, Jones M, Rowe M. Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 2001; 276: 1195–1203
   PubMed Web of Science ®Google Scholar
• Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389–399
   PubMed Web of Science ®Google Scholar
• Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidle R, et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J 1997; 16: 6131–6140
   PubMed Web of Science ®Google Scholar
• Mcfarland E DC, Izumi K M, Mosialos G. Epstein–Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene 1999; 19: 6959–6964
   Web of Science ®Google Scholar
• Yang X, He Z, Xin B, Cao L. LMP1 of Epstein–Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression. Oncogene 2000; 19: 2002–2013
   PubMed Web of Science ®Google Scholar
• Hardie D G, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annu Rev Biochem 1998; 67: 821–855
   PubMed Web of Science ®Google Scholar
• Salt I P, Johnson G, Ashcroft S J, Hardie D G. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 1998; 335: 533–539
   PubMed Web of Science ®Google Scholar
• Winder W W, Hardie D G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 1996; 270: E299–E304
   PubMed Web of Science ®Google Scholar
• Hardie D G, Scott J W, Pan D A, Hudson E R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 1996; 246: 113–120
   Google Scholar
• Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21: 6082–6090
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kusakai G I, Kishimoto A, Minegichi Y, Ogura T, Esumi H. Induction of cell–cell detachment during glucose starvation through F-actin conversion by SNARK, the fourth member of the AMP-activated protein kinase catalytic subunit family. Biochem Biophys Res Comm 2003; 311: 156–161
   PubMed Web of Science ®Google Scholar
• Robertson M J, Cochran K J, Cameron C, Le J M, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406–415
   PubMed Web of Science ®Google Scholar
• Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, et al. Establishment of an IL-2-dependent cell line derived from ‘nasal-type’ NK/T-cell lymphoma of CD2+, sCD3−, CD3epsilon+, CD56+ phenotype and associated with the Epstein–Barr virus. Br J Haematol 1998; 103: 669–677
   PubMed Web of Science ®Google Scholar
• Kim J H, Kim W S, Kang J H, Yim H Y, Ko Y, Park C. Egr-1, a new downstream molecule of Epstein–Barr virus latent membrane protein 1. FEBS Lett 2007; 581: 623–628
   PubMed Web of Science ®Google Scholar
• Lefebvre D L, Rosen C F. Regulation of SNARK activity in response to cellular stresses. Biochim Biophys Acta 2005; 1724: 71–85
   PubMed Web of Science ®Google Scholar
• Kim K, Ryu K, Kho Y, Park C. Effects of NF-κB inhibitors and its implication on NK/T cell lymphoma cells. Br J Haematol 2005; 131: 59–66
   PubMed Web of Science ®Google Scholar
• Kurosu T, Fukuda T, Miki T, Miura O. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 2003; 22: 4459–4468
   PubMed Web of Science ®Google Scholar
• Chu Z L, McKinsey T A, Liu L, Gentry J J, Malim M H, Ballard D W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci 1997; 94: 10057–10062
   PubMed Web of Science ®Google Scholar
• Legembre P, Schickel R, Barnhart B C, Peter M E. Identification of SNF1/AMP kinase-related kinase as an NF-κB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem 2004; 279: 46742–46747
   PubMed Web of Science ®Google Scholar